SAB Biotherapeutics (SABS)
Develops a fully human polyclonal-antibody therapy for newly diagnosed autoimmune diabetes.
$3.38
vs last close−0.12 (−3.43%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 75.29% | 68.50M shares | |
|---|---|---|---|
| 92 holders · as of Jun 30, 2026 | |||
| Insiders | 0.05% | 41.9K shares | |
| 1 holder · as of Sep 18, 2026 | |||
| Other | 24.66% | 22.44M shares | |
| remainder | |||
90.99M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
92 holders · 68.50M shares · 31 new positions · 57 increased · 17 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Caligan Partners LP | 7.97M | 8.76% | 0 | Aug 14, 2026 |
| Vivo Capital, LLC | 7.30M | 8.02% | −4.12M | Aug 14, 2026 |
| Perceptive Advisors LLC | 6.63M | 7.28% | +195.8K | Aug 14, 2026 |
| Adage Capital Partners GP, L.L.C. | 6.41M | 7.04% | +3.00M | Aug 14, 2026 |
| Ra Capital Management, L.P. | 4.40M | 4.84% | 0 | Aug 14, 2026 |
| Balyasny Asset Management L.P. | 3.76M | 4.13% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 3.07M | 3.37% | +2.76M | Aug 7, 2026 |
| Vanguard Capital Management LLC | 2.97M | 3.27% | +479.2K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Caligan Partners LP | 10.40% | 7.70M | 13G | May 15, 2026 |
| Balyasny Asset Management L.P. | 9.99% | 5.09M | 13G | May 15, 2026 |
| Vivo Opportunity Fund Holdings, L.P. | 9.99% | 25.93M | 13G | Oct 3, 2025 |
| Rajeev Shahincl. RA Capital Management, L.P., RA Capital Healthcare Fund, L.P. +1 more | 9.90% | 9.61M | 13D | Aug 10, 2026 |
| Woodline Partners LP | 9.90% | 7.13M | 13G | Nov 14, 2025 |
| Commodore Capital LP | 9.90% | 4.52M | 13G | Oct 3, 2025 |
| Perceptive Advisors LLC | 8.40% | 6.43M | 13G | May 15, 2026 |
| Adage Capital Management, L.P. | 8.38% | 6.41M | 13G | Aug 12, 2026 |
| Millennium Management LLC | 5.10% | 3.43M | 13G | May 1, 2026 |
| Biotechnology Value Fund L P | 5.10% | 2.54M | 13G | Feb 17, 2026 |
Form 4
Latest trades
No open-market trades in the last 12 months.
House and Senate disclosures
Not reported.